Search

Your search keyword '"Mcadam, K"' showing total 673 results

Search Constraints

Start Over You searched for: Author "Mcadam, K" Remove constraint Author: "Mcadam, K" Publication Year Range Last 50 years Remove constraint Publication Year Range: Last 50 years
673 results on '"Mcadam, K"'

Search Results

2. Final results from the PERUSE study of first-line pertuzumab plus trastuzumab plus a taxane for HER2-positive locally recurrent or metastatic breast cancer, with a multivariable approach to guide prognostication

3. Scheduling nab-paclitaxel combined with gemcitabine as first-line treatment for metastatic pancreatic adenocarcinoma

7. Disease-free and overall survival at 3.5 years for neoadjuvant bevacizumab added to docetaxel followed by fluorouracil, epirubicin and cyclophosphamide, for women with HER2 negative early breast cancer: ARTemis Trial

16. SAA Isotypes in Patients with Secondary Amyloidosis

19. Final results from the PERUSE study of first-line pertuzumab plus trastuzumab plus a taxane for HER2-positive locally recurrent or metastatic breast cancer, with a multivariable approach to guide prognostication

25. Optimising the Duration of Adjuvant Trastuzumab in Early Breast Cancer in the UK

28. Should chemotherapy in neoadjuvant setting in node positive breast cancers be guided by biology over magnitude of tumour burden?

29. LBA20 Vandetanib plus fulvestrant versus placebo plus fulvestrant after relapse or progression on an aromatase inhibitor in metastatic ER positive breast cancer (FURVA): A randomised, double-blind, placebo-controlled, phase II trial

47. Tuberculous meningitis

48. Corrigendum: Randomised, open-label, phase II study of gemcitabine with and without IMM-101 for advanced pancreatic cancer (British Journal of Cancer (2016) 115 (789-796) DOI: 10.1038/bjc.2016.271)

49. Corrigendum: Randomised, open-label, phase II study of gemcitabine with and without IMM-101 for advanced pancreatic cancer (British Journal of Cancer (2016) 115 (789-796) DOI: 10.1038/bjc.2016.271)

50. Randomised, open-label, phase II study of gemcitabine with and without IMM-101 for advanced pancreatic cancer

Catalog

Books, media, physical & digital resources